GlobeNewswire by notified

Infant Formula Producers Facing Crisis Can Rely on Southern California ProTab Labs for Safe Rapid Large-Scale Production of Premixes and Packaging Solutions

Share

Foothill Ranch, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- To tackle the infant formula crisis, producers can rely on Southern California supplement solutions contract manufacturer ProTab Laboratories to blend custom premixes and produce and package infant formula with a rapid turnaround time.

“ProTab is in the perfect position as a supplement solution manufacturer and packager to prioritize infant formula production with safety and scale to help replenish the supply in the market,” said Joanne Hsu, vice president of operations. “We are ready to produce safe, high-quality premixes with careful processing and top-quality standards at our facility for reassuring parents and babies that they will have access to quality and safe infant formula.”

Safety continues to be at the forefront of the crisis. ProTab has the capabilities of in-house analytical laboratory services for quality control validation, including analytical capabilities. The company is FDA registered with cGMP, FSMA, and FSSC 22000 certified by NSF.

“ProTab can rapidly turn around the production of powder and premix for liquid infant formula at a large scale to bolster the supply of products with proper FDA-inspected nutritional values and safety,” said Hsu. “Our certifications are the gold standard of safety for reassuring our manufacture of food and supplement solutions, including infant formula premix solutions.”

“As a GFSI certified producer and packager of supplement solutions, ProTab elevates food safety to the next level with our state-of-the-art facility, coupled with our quality control procedures and testing,” said Fariba Samadi, director of quality assurance and regulatory affairs. “Following stringent quality assurance and safety processes, we evaluate the quality of raw materials before manufacturing as well as the finished goods.”

Infant formula producers can leverage ProTab’s modern technology for precision blending needed for producing infant formula. Microencapsulation is offered to mask the undesirable characteristics of particular additives and formula ingredients. The technology is part of ProTab’s recent multimillion-dollar expansion to increase the footprint for blending and mixing premix solutions.

ProTab can also help secure the best materials and ingredients if needed; the company keeps up with the newest production and delivery technologies and the latest regulatory requirements and considers modern formulation and consumer trends.

For specific needs in labeling and standards, ProTab Labs can manufacture products to the specification of USDA Organic, Non-GMO Project Verified, Halal, and Kosher. The company is registered with Health Canada as a foreign manufacturer site.

“We encourage infant formula manufacturers and brand holders to bring their formulas and packaging schematics to work with us,” said Hsu. “We are confident in helping everyone get through the bottleneck together and positioning ProTab as a long-term infant formula production partner,” said Hsu.

###

About ProTab Laboratories
ProTab Laboratories is a custom research contract manufacturer operating a state-of-the-art facility in Southern California for providing rapid turnaround services for tablet, capsule, and powder form products, along with high-capacity mixing processes for nutritional and dietary supplements, tableting, microencapsulation, granulation, and milling. ProTab can guide brands through the product development and technical process from inception to the final product.

Contact us at info@protablabs.com.

For brands that would like to strengthen their vendor diversity profile, ProTab is also a certified Women-Owned Business Enterprise.

Certifications
ProTab's manufacturing operation is fully compliant with all current Good Manufacturing Practices (cGMP) established within the industry and meets or exceeds all quality standards for Nutritional Supplements. The company has established Standard Operating Procedures (SOP) to ensure that this standard is met in all manufacturing process phases. Our quality control standards are compliant with Kosher, Halal, Health Canada, USDA Organic, State of California Department of Public Health, NSF, and Non-GMO Project Verified.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Basilea reports progress on the implementation of its strategy to focus on anti-infectives27.6.2022 07:15:00 CEST | Press release

ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia (SAB) expected to report results shortlySeparate transactions for TTK/PLK1 inhibitor (BAL0891) and preclinical oncology projects expected to be concluded in H2 2022 No expansion of ongoing lisavanbulin clinical studies; exploring partnering opportunitiesDerazantinib rights to be transferred back to Merck & Co. by the end of 2022No material expenses related to oncology activities beyond 2022 and sustainable profitability expected in 2023Strategy implementation on track Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, June 27, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today an update on the progress made in the implementation of its strategic focus on anti-infectives. David Veitch, Chief Executive Officer, stated: “We have made significant progress in the implementation of our new strategy. Wit

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo